Stockscreener 앱 받기
12.12
4.57%
0.53
시간 외 거래:
12.12
전일 마감가:
$11.59
열려 있는:
$11.45
하루 거래량:
850.97K
Relative Volume:
1.17
시가총액:
$888.86M
수익:
$125.58M
순이익/손실:
$-92.14M
주가수익비율:
-9.7553
EPS:
-1.2424
순현금흐름:
$-138.27M
1주 성능:
+4.39%
1개월 성능:
+3.24%
6개월 성능:
+17.78%
1년 성능:
-7.76%
1일 변동 폭
$11.34
$12.30
1주일 범위
$11.34
$12.50
52주 변동 폭
$6.92
$18.69
Xencor Inc Stock (XNCR) Company Profile
명칭
Xencor Inc
전화
626-305-5900
주소
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
12.12 | 849.99M | 125.58M | -92.14M | -138.27M | -1.2424 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-10-29 | 업그레이드 | Barclays | Underweight → Overweight |
| 2025-09-17 | 재개 | Barclays | Underweight |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-04-21 | 개시 | William Blair | Outperform |
| 2024-12-12 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | 재확인 | BTIG Research | Buy |
| 2024-02-28 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | 개시 | BofA Securities | Buy |
| 2022-12-06 | 개시 | Cowen | Outperform |
| 2022-10-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-21 | 개시 | SMBC Nikko | Outperform |
| 2021-12-15 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-02-24 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | 개시 | Barclays | Underweight |
| 2020-02-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-01-30 | 개시 | RBC Capital Mkts | Outperform |
| 2019-11-20 | 재개 | Guggenheim | Neutral |
| 2019-08-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-08-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-04-12 | 개시 | Guggenheim | Buy |
| 2019-03-27 | 개시 | Berenberg | Buy |
| 2019-03-15 | 개시 | Raymond James | Outperform |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2017-03-02 | 개시 | Instinet | Neutral |
| 2017-03-02 | 재확인 | Wedbush | Outperform |
| 2016-10-04 | 개시 | Piper Jaffray | Overweight |
| 2015-12-22 | 개시 | Canaccord Genuity | Buy |
| 2015-08-05 | 재확인 | MLV & Co | Buy |
| 2015-02-12 | 재확인 | Oppenheimer | Outperform |
| 2015-01-28 | 재확인 | MLV & Co | Buy |
| 2014-07-11 | 개시 | Oppenheimer | Outperform |
모두보기
Xencor Inc 주식(XNCR)의 최신 뉴스
Aug Analyst Calls: What hedge funds are buying Xencor IncLong Setup & Daily Price Action Insights - baoquankhu1.vn
Macro Review: Will Xencor Inc stock hit new highs in YEAR2026 Top Decliners & Fast Momentum Entry Tips - baoquankhu1.vn
Retail Trends: Can Xencor Inc beat the S P 500Quarterly Growth Report & Expert Curated Trade Ideas - baoquankhu1.vn
Earnings Recap: Is Xencor Inc backed by strong institutional buying2026 Patterns & AI Optimized Trade Strategies - baoquankhu1.vn
Braidwell LP Lowers Holdings in Xencor, Inc. $XNCR - MarketBeat
Xencor, Inc. $XNCR Shares Purchased by Baker BROS. Advisors LP - MarketBeat
Xencor’s Lung Cancer Trial Halted: What the Vudalimab Update Means for XNCR Investors - TipRanks
Jefferies Financial Group Inc. Takes Position in Xencor, Inc. $XNCR - MarketBeat
Xencor at Barclays Healthcare Conference: Pipeline Progress and Strategic Plans - Investing.com India
Xencor at Barclays Healthcare Conference: Pipeline Progress and Strategic Plans By Investing.com - Investing.com South Africa
(XNCR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Xencor at Leerink Global Healthcare: Strategic Development Insights - Investing.com Nigeria
Xencor, Genentech to End Protein Therapeutics Collaboration - The Globe and Mail
Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Xencor SVP Eckert sells $17,747 in shares - Investing.com Nigeria
Xencor faces royalty dispute with Alexion over Ultomiris sales - Investing.com Nigeria
Xencor (NASDAQ:XNCR) CEO Sells $72,798.12 in Stock - MarketBeat
John Desjarlais Sells 4,118 Shares of Xencor (NASDAQ:XNCR) Stock - MarketBeat
Xencor (NASDAQ:XNCR) SVP Sells $19,472.34 in Stock - MarketBeat
Xencor (NASDAQ:XNCR) SVP Celia Eckert Sells 3,244 Shares - MarketBeat
Xencor (NASDAQ:XNCR) VP Sells $27,572.04 in Stock - MarketBeat
Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 14,870 Shares - MarketBeat
Xencor (XNCR) SVP and general counsel sells 5,011 shares for RSU tax - Stock Titan
Xencor (XNCR) CFO sells 2,517 shares to cover RSU tax withholding - Stock Titan
Xencor (XNCR) CEO sells 21,476 shares to cover RSU tax obligations - Stock Titan
Genentech ends Xencor (NASDAQ: XNCR) efbalropendekin alfa license deal - Stock Titan
Royalty rift: Alexion cuts off US royalty payments to Xencor - MSN
Market Moves: What is the Moat Score of Xencor IncMarket Volume Summary & Weekly Watchlist of Top Performers - baoquankhu1.vn
Is Xencor Inc a strong candidate for buy and hold2025 Top Decliners & AI Driven Stock Movement Reports - baoquankhu1.vn
Aug Breakouts: Can Xencor Inc disrupt its industry2025 Technical Patterns & Low Risk High Reward Ideas - baoquankhu1.vn
Insider Buy: Can Xencor Inc sustain its profitabilityJuly 2025 Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Insider Bassil I. Dahiyat sells and vests shares (XNCR) — 12/19/2025 to 03/05/2026 - Stock Titan
Retail Trends: Is Xencor Inc impacted by rising rates2025 Historical Comparison & Consistent Profit Trading Strategies - baoquankhu1.vn
Resistance Check: What is the long term forecast for Xencor Inc stock2025 Key Highlights & Community Consensus Picks - baoquankhu1.vn
Xencor, Inc. $XNCR Shares Sold by Vanguard Group Inc. - MarketBeat
RBC Capital Reaffirms Their Buy Rating on Xencor (XNCR) - The Globe and Mail
Dahiyat, Xencor CEO, sells $80k in XNCR stock By Investing.com - Investing.com Australia
3,244-share sale planned by XNCR (NASDAQ: XNCR) — insider notice - Stock Titan
Insider sale and restricted vesting reported by Company (NASDAQ: XNCR) - Stock Titan
[144] Xencor Inc SEC Filing - Stock Titan
Xencor SVP Eckert sells $17,747 in shares By Investing.com - Investing.com Australia
Xencor faces royalty dispute with Alexion over Ultomiris sales By Investing.com - Investing.com Australia
Xencor (NASDAQ:XNCR) Shares Gap Down Following Insider Selling - MarketBeat
Xencor falls on royalty row with AstraZeneca (XNCR:NASDAQ) - Seeking Alpha
Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor - Bitget
Xencor (NASDAQ:XNCR) VP Sells $31,689.70 in Stock - MarketBeat
Insider Selling: Xencor (NASDAQ:XNCR) SVP Sells 1,492 Shares of Stock - MarketBeat
Xencor sr. VP Desjarlais sells $31,676 in stock - Investing.com South Africa
Xencor sr. VP Desjarlais sells $31,676 in stock By Investing.com - Investing.com Canada
Dahiyat, Xencor CEO, sells $80k in XNCR stock - Investing.com
Xencor (NASDAQ: XNCR) CEO awarded options, sells stock for taxes - Stock Titan
Xencor Inc (XNCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):